Current Systemic Treatment Strategies for Hidradenitis Suppurativa

The document from January 20, 2017, reviews systemic treatment strategies for hidradenitis suppurativa (HS), a chronic inflammatory skin condition. It discusses the use of antibiotics, retinoids, hormonal therapies, zinc salts, cyclosporine A, and biologics as treatment options. Adalimumab (ADA) is highlighted as the most effective biologic for severe and moderate HS, supported by the PIONEER I and II trials. Infliximab (IFX) also showed efficacy in a study with 38 subjects. Other biologics like etanercept (ETA), anakinra (ANA), and ustekinumab (UST) have varying degrees of effectiveness, with ANA showing promising results in smaller trials. The document emphasizes the need for early treatment to prevent irreversible disease consequences and suggests that while ADA and IFX can be safely initiated, other biologics require further evaluation. The treatment strategy often involves surgery, supported by medical treatment, and the document calls for more research to improve medical treatment strategies for HS.